Dynamic Advisor Solutions LLC Buys 1,120 Shares of Thermo Fisher Scientific Inc. $TMO

Dynamic Advisor Solutions LLC increased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 22.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,028 shares of the medical research company’s stock after buying an additional 1,120 shares during the quarter. Dynamic Advisor Solutions LLC’s holdings in Thermo Fisher Scientific were worth $2,924,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. TIAA Trust National Association grew its holdings in Thermo Fisher Scientific by 10.5% during the second quarter. TIAA Trust National Association now owns 123,948 shares of the medical research company’s stock valued at $50,256,000 after purchasing an additional 11,817 shares during the period. Lombard Odier Asset Management Switzerland SA raised its stake in Thermo Fisher Scientific by 8.4% during the 2nd quarter. Lombard Odier Asset Management Switzerland SA now owns 14,490 shares of the medical research company’s stock worth $5,875,000 after buying an additional 1,128 shares during the period. Caledonia Investments PLC lifted its holdings in Thermo Fisher Scientific by 11.5% during the second quarter. Caledonia Investments PLC now owns 111,767 shares of the medical research company’s stock worth $45,299,000 after acquiring an additional 11,500 shares in the last quarter. Heritage Investors Management Corp grew its stake in Thermo Fisher Scientific by 9.6% in the second quarter. Heritage Investors Management Corp now owns 56,587 shares of the medical research company’s stock valued at $22,944,000 after acquiring an additional 4,971 shares during the period. Finally, LBP AM SA raised its position in shares of Thermo Fisher Scientific by 13.4% during the second quarter. LBP AM SA now owns 261,038 shares of the medical research company’s stock worth $105,840,000 after purchasing an additional 30,837 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, COO Michel Lagarde sold 32,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the transaction, the chief operating officer directly owned 65,480 shares in the company, valued at approximately $38,200,377.20. The trade was a 32.83% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 17,104 shares of the stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This represents a 13.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 149,271 shares of company stock valued at $86,507,282 in the last ninety days. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Up 0.8%

Shares of TMO stock opened at $567.01 on Friday. The firm’s fifty day moving average price is $569.01 and its two-hundred day moving average price is $497.40. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $213.03 billion, a P/E ratio of 32.76, a PEG ratio of 4.21 and a beta of 0.90.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the company earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a share repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares buyback programs are generally a sign that the company’s management believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.94%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Hsbc Global Res upgraded Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Monday, December 1st. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the company an “outperform” rating in a report on Tuesday, September 2nd. The Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective on the stock. Evercore ISI upped their target price on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Finally, KeyCorp raised Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price target on the stock in a research note on Sunday, December 7th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $616.60.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.